-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Diamyd in Latent Autoimmune Diabetes of Adulthood (LADA)/ Type 1.5 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Diamyd in Latent Autoimmune Diabetes of Adulthood (LADA)/ Type 1.5 Diabetes report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Diamyd in Latent Autoimmune Diabetes of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cariprazine in Autism Spectrum Disorder (ASD)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cariprazine in Autism Spectrum Disorder (ASD) Drug Details: Cariprazine (RGH -188, Vraylar, Reagila, Symvenu)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VB-119 in Focal Segmental Glomerulosclerosis (FSGS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VB-119 in Focal Segmental Glomerulosclerosis (FSGS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VB-119 in Focal Segmental Glomerulosclerosis (FSGS) Drug Details: VB-119 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DSP-0390 in High-Grade Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DSP-0390 in High-Grade Glioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.DSP-0390 in High-Grade GliomaDrug Details:DSP-0390 is under development for the treatment of solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HH-2853 in Peripheral T-Cell Lymphomas (PTCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HH-2853 in Peripheral T-Cell Lymphomas (PTCL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HH-2853 in Peripheral T-Cell Lymphomas (PTCL) Drug Details: HH-2853...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vanucizumab in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vanucizumab in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vanucizumab in Solid Tumor Drug Details: Vanucizumab is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Deupirfenidone in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Deupirfenidone in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Deupirfenidone in Idiopathic Pulmonary Fibrosis Drug Details: Deupirfenidone (SD-560, LYT-100) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMG-193 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMG-193 in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.AMG-193 in Pancreatic Cancer Drug Details:AMG-193 is under development for treatment of metastatic...
-
Product Insights
Elite GAD Invest – Watson Road Mixed-Use Development – Texas
Equip yourself with the essential tools needed to make informed and profitable decisions with our Elite GAD Invest - Watson Road Mixed-Use Development - Texas report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Product Insights
NEA – Nalsing Gad Hydroelectric Power Plant 410 MW – Mid Western
Equip yourself with the essential tools needed to make informed and profitable decisions with our NEA - Nalsing Gad Hydroelectric Power Plant 410 MW - Mid Western report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story:...